Companies › Coherus Oncology
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Casdozokitug Soluble guanylate cyclase stimulator | GUCY1A1, GUCY1B1 | Phase 2 | Hepatocellular Carcinoma | Sep 2027 |
| CHS-114 | – | Phase 1 | Advanced Solid Tumor; Metastatic Solid Tumor | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05635643 | CHS-114 | Phase 1 | Advanced Solid Tumor | Oncology | Jan 2027 |
| NCT06679985 | Casdozokitug | Phase 2 | Hepatocellular Carcinoma | Oncology | Sep 2027 |
| NCT06657144 | CHS-114 | Phase 1 | Metastatic Solid Tumor | Oncology | Jan 2028 |
Cash and short-term investments of $84m on 2026-09-30; operating cash outflow about $207m a year; runway about 5 months at that burn, to Feb 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Merck & Co. (MSD) Pulmovant Kardigan Bayer Akebia Therapeutics
Neonc Technologies Agenus Lantern Pharma Innate Pharma Oncolytics Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.